Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.61 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945486 | 0.88 | KDM4E (0.56) | PRMT5GPR119NPC1RAB9AADAM17 | |
| SCHEMBL1103900 | 0.85 | PRMT5 (0.52) | PRMT5RORCGPR119NPC1RAB9A | |
| SCHEMBL2155344 | 0.82 | MAPT (0.59) | PRMT5RORCNPC1RAB9AMAPT | |
| SCHEMBL11956908 | 0.80 | RAB9A (0.52) | NPC1RAB9AMAPTHTTLMNA | |
| SCHEMBL5214510 | 0.80 | ME2 (0.57) | GPR119NPC1RAB9AMAPTHTT | |
| Acetic Acid SCHEMBL27439012 | 0.80 | P4HTM (0.53) | GPR119NPC1RAB9AMAPTHTT | |
| SCHEMBL26077367 | 0.80 | ALDH1A1 (0.54) | PRMT5GPR119NPC1RAB9AMAPT | |
| SCHEMBL3943472 | 0.79 | GAA (0.46) | RORCGPR119NPC1RAB9ALMNA | |
| SCHEMBL2309052 | 0.78 | NTRK1 (0.64) | PRMT5NPC1RAB9AMAPTHTT | |
| SCHEMBL31104885 | 0.78 | PRMT5 (0.57) | PRMT5NPC1RAB9AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102229589-A | N-{4'-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB | 2011-11-02 | — | — | CN | disclosed |
| CN-1812974-B | N- {' 4-substituted piperazine-1-sulfonylmethyl alkyl } -N-hydroxyformamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB | 2011-06-29 | — | — | CN | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| CN-1812974-A | N- {' 4-substituted piperazine-1-sulfonylmethyl alkyl } -N-hydroxyformamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | PRMT5 1448/4885RORC 3245/4885GPR119 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.